KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Short-Term Debt repayments

Daily Values

Growth Metrics

Organon (OGN) Asset Writedowns and Impairment (2021)

Organon has reported Asset Writedowns and Impairment over the past 1 years, most recently at $7.0 million for Q4 2021.

For Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $7.0 million; the TTM value through Sep 2023 reached $7.0 million, changed N/A, while the annual FY2025 figure was $9.0 million, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2021 was $7.0 million at Organon.
Over five years, Asset Writedowns and Impairment peaked at $7.0 million in Q4 2021 and troughed at $7.0 million in Q4 2021.